What KOLs say: Prof. Ih-Jen Su on Taiwan's biotech industry through the lens of the MVC COVID-19 Vaccine incident.
 
The development of COVID-19 vaccines has presented a robust competition model for the biotech industry. Only companies with solid financials, expertise, talent pool, integrated supply chains, and market presence can thrive and become leaders. The unexpected turn of events with the Medigen Vaccine Biologics’s MVC COVID-19 Vaccine has woven a complex narrative, turning it into a political matter and introducing various challenges.
 
Join the conversation with #Globalbio for insightful updates! 
#Biotech #COVID19 #Vaccine #BIOInsights #MVC
 
Read more: https://news.gbimonthly.com/tw/article/show.php?num=6433